Voyager Therapeutics Q2 2024 GAAP EPS $(0.18) Beats $(0.43) Estimate, Sales $29.578M Beat $9.461M Estimate
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics (NASDAQ:VYGR) reported Q2 2024 GAAP EPS of $(0.18), beating the $(0.43) estimate. Sales were $29.578M, surpassing the $9.461M estimate and showing a 509.48% increase from the same period last year.
August 06, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Voyager Therapeutics reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.18) beating the $(0.43) estimate and sales of $29.578M surpassing the $9.461M estimate. This represents a significant 509.48% increase in sales from the same period last year.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, is likely to positively impact Voyager Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100